Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

Abstract

Combining an ATRi or Chk1i with olaparib is synergistic in both PARPi-sensitive and -resistant <i>BRCA1</i> mutated OC cell models, and are rationale combinations for further clinical development.